Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT

Summary

This is a Phase 2 study designed for the purpose of estimating various parameters surrounding the efficacy of Clofarabine, Cyclophosphamide and Etoposide in eliminating minimal residual disease (MRD) in acute leukemia patients otherwise in remission and without causing significant delay of HCT due to treatment related toxicity. A single course of "bridge" chemotherapy is given prior to the transplant procedure as an approach to improved disease-free survival in a patient group who historically has had inferior outcomes.

Timeline

Start

2014-12-08

Primary completion

2017-03-16

Completion

2017-03-16

Drugs

Indications